{"Title": "Con: The Unclear Benefit of Albumin", "Year": 2019, "Source": "Liver Transplant.", "Volume": "25", "Issue": 1, "Art.No": null, "PageStart": 135, "PageEnd": 139, "CitedBy": 2, "DOI": "10.1002/lt.25384", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85059495115&origin=inward", "Abstract": "Copyright \u00a9 2018 by the American Association for the Study of Liver Diseases.Many studies have shown that 20% human albumin solution infusions improve circulatory function in patients with advanced liver disease, and this treatment is widely recommended and used by all hepatologists. However, it is more expensive than other crystalloids or colloids, and several countries suffer shortages of supply. This article examines whether other fluids might be considered for these patients.", "AuthorKeywords": null, "IndexKeywords": ["Clinical Trials as Topic", "Colloids", "Crystalloid Solutions", "End Stage Liver Disease", "Fluid Therapy", "Humans", "Infusions, Intravenous", "Liver Transplantation", "Plasma Substitutes", "Practice Guidelines as Topic", "Serum Albumin, Human", "Treatment Outcome"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 0, "EID": "2-s2.0-85059495115", "SubjectAreas": [["Surgery", "MEDI", "2746"], ["Hepatology", "MEDI", "2721"], ["Transplantation", "MEDI", "2747"]], "AuthorData": {"57205315141": {"Name": "O\u2019Brien A.", "AuthorID": "57205315141", "AffiliationID": "60022148", "AffiliationName": "Institute of Liver Disease and Digestive Health, University College London"}}}